Owkin signs AI drug discovery deal with Boehringer for cancer, immunology

By Sahil Pandey Sept 2 (Reuters) - AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and .